About Us

Mind Medicine Australia is a registered charity working to alleviate the suffering and suicides caused by mental illness by expanding treatment options through the safe, clinical use of psychedelic-assisted therapies to treat depression, trauma, addictions and other intractable conditions. MMA’s wholly clinical focus includes building a national ecosystem encompassing professional development for health practitioners through the world-leading Certificate in Psychedelic-Assisted Therapies (CPAT), patient access pathways, medicine supplies, regulatory and research advancements, clinical rollouts and widespread awareness and education. MMA made global history through their successful rescheduling applications for psilocybin and MDMA making Australia the first nation in the world to reschedule these medicines for clinical use in 2023.

Indications of success

• These therapies become an integral part of our Mental Health System
• With high remission rates leading to a substantial improvement in our Mental Health Statistics
• And that these therapies are accessible and affordable to all Australians in need

Four key strategic areas

Inclusivity

Mind Medicine Australia is committed to creating a diverse and inclusive environment and is proud to be an equal opportunity employer. All qualified applicants receive consideration for employment without regard to race, colour, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, age, or veteran status. Mind Medicine Australia associated practitioners also offer an inclusive and safe place for patients to receive care. We respect and value the cultural differences between us.

Research

We support and fund clinical psychedelic research, conducted by independent institutions and affiliates.

Partnerships

By developing relationships between government, academic institutions, interest groups and regulatory bodies, Mind Medicine Australia aims to facilitate evidence-based change.

Education & Events

We educate the general public, medical and mental health practitioners, regulators, and other stakeholders on clinical psychedelic research and therapeutic application.

Training

Mind Medicine Australia will act as the interface between research and practice by translating clinical research into accredited therapist training protocols, such as with our Certificate in Psychedelic-Assisted Therapies (CPAT)™.

Our achievements in the first 6 years

Key Achievements

 

• Successful Rescheduling of Medicines
  Our advocacy led to the rescheduling of psilocybin and MDMA, making them legally prescribable by psychiatrists across Australia for treatment-resistant depression (psilocybin) and PTSD (MDMA). This milestone has positioned Australia and our charity as global leaders in the clinical application of psychedelic-assisted therapies. We are now actively working to extend rescheduling to palliative care, enabling therapeutic use for people with terminal illness to address depression and anxiety.
• Training Over 500 Clinicians
  Including psychiatrists, GPs, psychologists, psychotherapists and more, through our Certificate in Psychedelic-Assisted Therapies (CPAT™) which is regularly referred to as the world’s best.
• Largest Importer of Medicines
  We are the largest importer of these medicines into Australia, ensuring reliable access for therapeutic use.
• Launching New Clinics and providing Support for Clinic Infrastructure
  We are actively launching and supporting new clinics. We provide “how-to” guides and operational resources to new clinics and are developing clinic software systems to enhance patient experience and reduce costs.
• Government Engagement and Policy Change
  Advocating at Federal, State, and Territory levels for more efficient and less costly regulatory processes. This has led directly to more streamlined regulatory approaches in both Victoria and New South Wales.
• Research and Data Infrastructure
  – Funded clinical trials for OCD and other mental illnesses
  – Supported and funded an ANU-led Real World Evidence Registry for psychedelic-assisted therapies, the first of its kind globally
• Funding Milestone
  Our advocacy directly led to the largest-ever Australian Government grant for psychedelic research: $15 million awarded in 2021 through the Medical Research Future Fund (the largest government grant globally to supported research into psychedelic assisted therapies for mental health treatments.
• Financial Assistance for Patients
  Established and operate the Patient Support Fund, providing over $100,000 in financial support for 10 patients to undergo psychedelic-assisted therapies in its first year.
• Insurance and Reimbursement Advocacy
  Presenting to private insurers and governments to encourage patient subsidies for psychedelic-assisted therapies.

Other Achievements

 

Training & Education

• Educated over 3500 people across all programs (workshops, CPAT™, online courses, Global Summit)
• Participants from every Australian state and 20+ other countries
• Launched Australia’s first accredited psychedelic training course (CPAT™)
• Delivered 230+ webinars and a 56-episode podcast series featuring global leaders
• Developed a BLOG, extensive education resources, and partnered with universities to share them

Public Awareness & Engagement

• Website: 551,000+ page views
• YouTube: 684,000+ views, 5371+ subscribers
• Social Media: 101,700+ followers
• Mailing List: 47,000+ subscribers (within a broader 72,000+ person engaged database)
• National Chapters Network: 30+ chapters, 2200+ members
• Events: Special events and documentary screenings with 42,000+ participants
• Media: Featured in 350+ major media outlets
• Published Australia’s first Book of Psychedelic Healing Stories
• Sold-out launch event with Professor David Nutt at the University of Melbourne

Sector Leadership & Stakeholder Engagement

• Established a world-class Board, Ambassador network, Advisory Panel, Young Leaders, and Lived Experience Panels
• Built strong ties with key stakeholders across academia, health, and regulatory sectors
• Developing a gold-standard National Care Program with clinical partners

Research, Events & Policy

• Supported numerous clinical trials including OCD and healthy volunteer studies
• Collaborating on medicine manufacturing in Australia
• Hosted the Southern Hemisphere’s largest psychedelic summit (2021), featuring: 1000+ participants, 30+ global speakers, 180+ partner organisations and 80,000+ website visits
• Made key submissions to government inquiries and commissions, influencing mental health policy nationwide